ReviewJournal of molecular cell biology2016
Adiponectin, the past two decades.
Review in Journal of molecular cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 342 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
342 citing papers in PubMed, 4 syntheses or guidelines pooled it, 603 citations in OpenAlex.
- Effects of various exercise types on inflammatory response in individuals with overweight and obesity: a systematic review and network meta-analysis of randomized controlled trials.International journal of obesity (2005) · 2025Pooled it
- Unveiling the perfect workout: exercise modalities and dosages to ameliorate adipokine dysregulation in individuals with overweight and obesity: a systematic review with pairwise, network, and dose-response meta-analyses.Frontiers in nutrition · 2025Pooled it
- Exploring the logic and conducting a comprehensive evaluation of AdipoRon-based adiponectin replacement therapy against hormone-related cancers-a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- The role of adiponectin in Alzheimer's disease: A translational review.The journal of nutrition, health & aging · 2024Pooled it
- Effects of Acute Low- and Moderate-Dose Alcohol on Chronic Disease-Related Biomarkers in Healthy Light and Heavy Drinkers.Alcohol, clinical & experimental research · 2026Trial
- The Effect of Maternal Antioxidant Vitamin Supplementation on Maternal and Cord Blood Adiponectin Concentrations.American journal of perinatology · 2025Trial
- Consuming a Protein and Fiber-Based Supplement Preload Promotes Weight Loss and Alters Metabolic Markers in Overweight Adults in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.The Journal of nutrition · 2022Trial
- Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications.Archives of dermatological research · 2021Trial
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Sphingomyelin as a key negative mediator in atrial fibrillation via lipid profiling analysis and functional identification.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Human Adipose Allograft Restores Volume Through Host-mediated Tissue Replacement.Plastic and reconstructive surgery. Global open · 2026Article
- Hypothalamus-Peripheral Organ Crosstalk in Energy Metabolism: A Bidirectional Regulatory Network.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Reduced Serum Endostatin in Premenopausal Women with Lipedema Suggests Altered Vascular Homeostasis.Diseases (Basel, Switzerland) · 2026Article
- Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinic.Metabolic brain disease · 2026Article
- Deletion of Tgf-β1 From CD206Journal of cachexia, sarcopenia and muscle · 2026Article
- New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Adiponectin and aging: Mechanistic insights, clinical paradox, and therapeutic horizons.Ageing research reviews · 2026Review
- Mesenteric adipose tissue: from protective gatekeeper to driver of inflammatory bowel disease.Immunometabolism (Cobham, Surrey) · 2026Review
- Adiponectin modulates the diurnal hepatic transcriptome and energy metabolism in male mice.Endocrine connections · 2026Article
- Anti-Angiogenic Features of Endostatin in Obesity, Liver Fibrosis, and Hepatocellular Carcinoma.Biomedicines · 2026Review
282 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Adiponectin is an adipocyte-specific factor, first described in 1995. Over the past two decades, numerous studies have elucidated the physiological functions of adiponectin in obesity, diabetes, inflammation, atherosclerosis, and cardiovascular disease. Adiponectin, elicited through cognate receptors, suppresses glucose production in the liver and enhances fatty acid oxidation in skeletal muscle, which together contribute to a beneficial metabolic action in whole body energy homeostasis. Beyond its role in metabolism, adiponectin also protects cells from apoptosis and reduces inflammation in various cell types via receptor-dependent mechanisms. Adiponectin, as a fat-derived hormone, therefore fulfills a critical role as an important messenger to communicate between adipose tissue and other organs. A better understanding of adiponectin actions, including the pros and cons, will advance our insights into basic mechanisms of metabolism and inflammation, and potentially pave the way toward novel means of pharmacological intervention to address pathophysiological changes associated with diabetes, atherosclerosis, and cardiometabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.